Last Updated: June 25, 2026

Litigation Details for Eight Sleep Inc. v. Orion Longevity Inc (C.D. Cal. 2026)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Eight Sleep Inc. v. Orion Longevity Inc
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation summary and analysis for: Eight Sleep Inc. v. Orion Longevity Inc (C.D. Cal. 2026)

Last updated: June 25, 2026

Eight Sleep Inc. v. Orion Longevity Inc. (D. Del.) Patent and Licensing Litigation Summary (Case 2:26-cv-02460)

No complete, citable litigation summary can be produced from the information provided. The request specifies only the caption, court case number (2:26-cv-02460), and party names, with no docket content, asserted claims, patent numbers, complaint or answer details, claim construction, motion outcomes, or settlement/disposition terms.

What patents are asserted in Eight Sleep Inc. v. Orion Longevity Inc. (2:26-cv-02460)?

Answer: Not available from the provided input.

Which intellectual property rights are at issue (patents, trade secrets, copyrights, trademarks)?

Not available from the provided input.

What claim elements are alleged to be infringed?

Not available from the provided input.

When was the complaint filed and what procedural milestones exist in 2:26-cv-02460?

Answer: Not available from the provided input.

Key dates

  • Complaint filing date: not available
  • Service/answer deadlines: not available
  • Markman date: not available
  • Motions to dismiss decided: not available
  • Preliminary injunction motions: not available
  • Summary judgment motions: not available
  • Trial setting or scheduling order: not available

What motions and rulings drive the case posture?

Answer: Not available from the provided input.

Rule 12 motions

Not available from the provided input.

Claim construction (Markman)

Not available from the provided input.

Discovery disputes and protective orders

Not available from the provided input.

What does Orion Longevity’s infringement defense strategy look like?

Answer: Not available from the provided input.

Non-infringement positions

Not available from the provided input.

Invalidity positions (anticipation, obviousness, indefiniteness, written description)

Not available from the provided input.

Prosecution history estoppel / claim scope arguments

Not available from the provided input.

Does the case involve a licensing agreement or prior commercial dispute?

Answer: Not available from the provided input.

License terms, termination, and royalty provisions

Not available from the provided input.

Breach-of-contract or declaratory judgment claims

Not available from the provided input.

How does the asserted technology map to the accused products (mattress sleep systems, sensors, control algorithms)?

Answer: Not available from the provided input.

Accused product components

Not available from the provided input.

Alleged use cases and method claims

Not available from the provided input.

What is the litigation risk profile for Eight Sleep vs. Orion Longevity?

Answer: Not available from the provided input.

Injunction and irreparable harm exposure

Not available from the provided input.

Damages exposure (lost profits, reasonable royalty, enhanced damages)

Not available from the provided input.

Fee shifting and misconduct risk

Not available from the provided input.

What are likely outcomes and next steps given the current record?

Answer: Not available from the provided input.

Settlement likelihood drivers

Not available from the provided input.

Path to dismissal, summary judgment, or trial

Not available from the provided input.

Key Takeaways

No litigation summary or analysis can be generated for Eight Sleep Inc. v. Orion Longevity Inc., 2:26-cv-02460, without docket-specific information (asserted patents, complaint allegations, motion rulings, and disposition terms).

FAQs

  1. What patents are listed in the docket for 2:26-cv-02460?
  2. Was a preliminary injunction sought or granted in Eight Sleep v. Orion?
  3. What claim construction outcomes shaped the infringement theory?
  4. Did the court decide any Rule 12 or summary judgment motions?
  5. Has the case been settled, dismissed, or proceeded to trial?

References (APA)

  1. No citable sources were provided in the input.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.